Very Small Breast Cancer, HER2 Positive, and Trastuzumab in Adjuvant Treatment

Authors: R. Vyzula
Authors‘ workplace: Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Published in: Klin Onkol 2010; 23(1): 21-24
Category: Reviews


Breast cancer patients with a tumor size of ≤ 1 cm are still rare but their number is increasing as a consequence of mammary screening. It is logical that the best adjuvant treatment in such cancers is often discussed with respect to the risk of relapse of the disease. The number of patients in clinical trials with very small breast cancer is quite low, and a specific clinical trial for such patients is not planned. Retrospective analysis of some clinical trials which included patients with breast cancer and with very small size shows the worse prognosis of patients with HER2 positive tumors. Indirectly, we can assume the application of adjuvant treatment with trastuzumab in such very small breast cancer. However, the decision should be individual with regards to further risk factors for the disease and risk of the treatment itself. This article is more a contemplation in order to provoke discussion on this provocative subject.

Key words:
breast cancer – very small tumors – trastuzumab – adjuvant treatment


1. Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2- positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 2009; 27(34): 5671– 5673.

2. Chia S, Norris B, Speers C et al. Human Epidermal Growth Factor Receptor 2 Overexpression as a Prognostic Factor in a Large Tissue Microarray Series of Node‑ Negative Breast Cancers. J Clin Oncol 2008; 26(35): 5697– 5704.

3. Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/ amplification in patients with small tumor size and node‑ negative breast cancer. J Clin Oncol 2009; 27(34): 5693– 5699.

4. Goldhirsch A, Wood WC, Gerber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18(7): 1133– 1144.

5. Gonzalez‑ Angulo AM, Litton JK, Broglio KR et al. High Risk of Recurrence for Patients with Breast Cancer who Have Human Epidermal Growth Factor Receptor 2- Positive, Node‑ Negative Tumors 1 cm or Smaller. J Clin Oncol 2009; 27(34): 5700– 5706.

6. Hanrahan EO, Valero V, Gonzales‑ Angulo AM et al. Prognosis and Management of Patients with Node‑ Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature. J Clin Oncol 2006; 24(13): 2113– 2122.

7. Joensuu H, Idoly J, Lundin M et al. Amplification of erbB2 and erbB2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT1N0M0 Breast Cancer: A Nationwide Population‑based Study. Clin Cancer Res 2003; 9(3): 923– 930.

8. Pagani A, Milani A, Freoni V et al. Clinical outcome of very small (<1 cm) HER2 positive breast cancer and the role of trastuzumab as adjuvant treatment. Ann Oncol 2008; 19 (Suppl 9): ix87– ix102. L2.

9. Piccart‑ Gebhart MJ, Procter M, Leyland‑ Jones B et al. Trastuzumab after Adjuvant Chemotherapy in HER2- Positive Breast Cancer. N Engl J Med 2005; 353: 1659– 1672.

10. Rodrigues MJ, Wassermann J, Albiges‑ Sauvin L et al. Treatment of node‑ negative infra‑ centimetric HER2+ invasive breast carcinomas: A joint AERIO/ REMAGUS study. J Clin Oncol 2009; 27 (Suppl; Abstr 517).

11. Tovey SM, Brown S, Doughty JC et al. Poor survival outcomes in HER2- positive breast cancer patiens with low‑ grade, node‑ negative tumours. Br J Cancer 2009; 100: 680– 683.

Paediatric clinical oncology Surgery Clinical oncology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account